University of Saskatchewan
A PERSPECTIVE IN CANINE MEDICINE FOR THE USE OF COPEPTIN AS A SURROGATE FOR PLASMA ARGININE VASOPRESSIN HORMONE
Abstract
dc:description.abstractArginine vasopressin (AVP), also referred to as antidiuretic hormone (ADH), plays a key role in water balance and vascular tone. Unfortunately, measurement of plasma AVP is hampered by its short in-vivo and ex-vivo half-life and significant challenges with the methodologic reliability of laboratory assays. For this reason, serum or plasma AVP has seldomly been measured in veterinary medicine, and no AVP assays are commercially available in North America for veterinary clinical use. The diagnostic steps for the investigation of polyuria-polydipsia (PUPD) disorders have therefore been relying on the difficult and potentially dangerous modified water deprivation test (MWDT) and/or desmopressin acetate (DDAVP) therapeutic trial. In humans, the limitations of plasma AVP measurement have been overcome by the measurement of plasma copeptin (CoP). Copeptin is a 39-amino acid glycopeptide comprising the C-terminal part of the AVP preprohormone precursor and is co-secreted with AVP in an equimolar amount. Contrary to plasma AVP, CoP in serum or plasma is a relatively stable peptide, does not require the adjunction of a protease inhibitor during collection, and can be run on fast and automated assays. Plasma CoP measurement has been extensively studied over the past two decades in the human literature and has now replaced the measurement of plasma AVP in human medicine, including in clinical settings. The establishment of diagnostic cut-offs has revolutionized the diagnosis of primary polydipsia (PP), central diabetes insipidus (CDI) and nephrogenic diabetes insipidus (NDI) in humans. These diagnostic cut-offs have been established based on resting (baseline) plasma CoP concentrations, and plasma CoP concentrations after osmotic-based and non-osmotic-based stimulation testing. The current literature reporting on the measurement of CoP in small animal medicine is scarce. The first chapter of this thesis offers an updated review of the physiology of water metabolism. While the synthesis, secretion and regulatory pathway of AVP is thoroughly described, the emphasis has been placed on CoP physiology, the current assays available in humans for its measurement, and its clinical use in human medicine as a biomarker of endocrine and non- endocrine disorders. The review article provides grounds for clinical research around CoP in veterinary medicine. The second chapter of this thesis evaluated serum CoP as a potential surrogate for plasma AVP measurement in healthy dogs, by measuring both peptides under osmotic and non-osmotic stimulation testing. Osmotic stimulation testing was performed by water deprivation (plasma hyperosmolarity) and water loading (plasma hypoosmolality), while non-osmotic stimulation testing was obtained by intravenous administration of L-arginine hydrochloride or oral administration of an arginine-based food supplement (BovrilTM). While a wide basal inter-individual variation in serum CoP measurement was observed, there was a strong correlation between the fraction of increase in plasma AVP and serum CoP concentrations during hypo-osmotic and hyper-osmotic stimulation tests. In fact, the fraction of increase in serum CoP after osmotic stimulation testing showed correlation with plasma osmolality (pOsm) and urine osmolality (uOsm) than the fraction of increase in plasma AVP. Unfortunately, no stimulation of serum CoP was observed during arginine-based stimulation testing. This study suggested that serum CoP may be a relevant surrogate for plasma AVP in dogs. The third chapter of this thesis assessed the impact of administration of the oral glucocorticoid prednisolone at a conventional immunosuppressive dose on plasma AVP and serum CoP concentrations in healthy dogs. Both plasma AVP and serum CoP significantly decreased over the 35-day course of oral prednisolone. These results suggested that chronic iatrogenic hypercortisolism induces marked impairment of the osmoregulation of AVP secretion, leading to a state of partial central diabetes insipidus. A positive correlation was obtained between plasma AVP and serum CoP, further corroborating the use of serum CoP as a surrogate for plasma AVP measurement. Furthermore, this study emphasized the importance of the use of protease inhibitors to preserve the fragile AVP peptide, even when the harvested plasma was immediately stored at -80°C until analysis. In a general discussion, this thesis ultimately outlines the role of plasma CoP in the diagnosis and monitoring of endocrine and non-endocrine disorders in humans, with the goal to encourage further research to validate CoP use in veterinary clinical settings. The development of canine CoP assays and the establishment of diagnostic cut-offs similarly to what has been reported in human medicine is strongly encouraged, as routine measurement of serum CoP in veterinary medicine could have a breakthrough impact on understanding the pathophysiology of PUPD disorders.
Degree
thesis:*- Name thesis:degree_name
- Doctor of Philosophy (Ph.D.)
- Level thesis:degree_level
- Doctoral
- Discipline thesis:degree_discipline
- Small Animal Clinical Sciences
- Department thesis:degree_department
- Western College of Veterinary Medicine
- Grantor
- University of Saskatchewan
- Year dc:date.issued
- 2025
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Paulin, Mathieu Victor
- Advisors dc:contributor.advisor
-
- Snead, Elisabeth
- Unniappan, Suraj
- Committee members dc:contributor.committeemember
-
- Mayer, Monique
- Loewen, Jennifer
- Cosford, Kevin
- Carr, Anthony
- Refardt, Julie
- Fisher, Thomas
- ORCID person:identifier.orcid
Subjects
dc:subject × 7Rights
- Language dc:language.iso
- en
Identifiers
dc:identifier.*- Handle dc:identifier.uri
- https://hdl.handle.net/10388/17520